Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 722 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... February 14, 2023 Why is Colorectal Cancer Rising Rapidly among Young Adults? November 5, 2020 With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 How to Strengthen Your Immune System: Part 1 September 17, 2020 Load more HOT NEWS Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia Binimetinib Contributes to the Efficacy and Safety Outcomes Observed with Encorafenib... Hiding in plain sight: How we can use immune cells to... New on NCI Websites for June 2018
